SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, disclosed today that it is featured in a bioterrorism industry article published in the latest issue of The Homeland Defense Journal. The article entitled "Do We Have The Medicines To Fight Terrorism?" reviews the current absence of treatments able to address bioterror threats, and discusses the Aethlon HemopurifierTM as a potential first-line countermeasure able to treat drug and vaccine resistant pathogens, including those genetically modified for increased virulence.
